Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Rating of "Moderate Buy" from Brokerages

Key Points

• Intellia Therapeutics has received a consensus rating of "Moderate Buy" from eighteen research firms, with an average 12-month price target of $27.11.
• The company reported $14.25 million in revenue for the last quarter, exceeding expectations, and saw a year-over-year revenue increase of 104.3%.
• Insider trading activities included EVP Edward J. Dulac III selling 7,462 shares while Director William J. Chase acquired 100,000 shares, indicating differing confidence levels among executives.

Intellia Therapeutics, Inc. (NASDAQ:NTLA - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the eighteen research firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and eleven have given a buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $27.1111.

A number of brokerages have recently commented on NTLA. Canaccord Genuity Group dropped their price target on Intellia Therapeutics from $74.00 to $54.00 and set a "buy" rating on the stock in a research report on Tuesday, June 3rd. Wedbush reaffirmed a "neutral" rating and set a $7.00 price target on shares of Intellia Therapeutics in a research report on Monday, June 16th. Wall Street Zen raised Intellia Therapeutics from a "sell" rating to a "hold" rating in a research report on Saturday, September 6th. Royal Bank Of Canada dropped their price target on Intellia Therapeutics from $25.00 to $21.00 and set an "outperform" rating on the stock in a research report on Friday, August 8th. Finally, Chardan Capital dropped their price target on Intellia Therapeutics from $68.00 to $60.00 and set a "buy" rating on the stock in a research report on Monday, August 11th.

Intellia Therapeutics Trading Up 1.2%

NTLA stock opened at $11.42 on Friday. The stock's fifty day simple moving average is $11.61 and its two-hundred day simple moving average is $9.61. Intellia Therapeutics has a 1-year low of $5.90 and a 1-year high of $23.76. The stock has a market cap of $1.23 billion, a P/E ratio of -2.43 and a beta of 2.28.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported ($0.99) earnings per share for the quarter, topping the consensus estimate of ($1.03) by $0.04. Intellia Therapeutics had a negative return on equity of 57.48% and a negative net margin of 908.48%.The business had revenue of $14.25 million for the quarter, compared to analysts' expectations of $12.26 million. During the same quarter in the previous year, the firm earned ($1.52) earnings per share. The business's revenue was up 104.3% on a year-over-year basis. As a group, analysts forecast that Intellia Therapeutics will post -5.07 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Edward J. Dulac III sold 7,462 shares of the business's stock in a transaction on Wednesday, July 23rd. The stock was sold at an average price of $14.02, for a total transaction of $104,617.24. Following the sale, the executive vice president directly owned 106,062 shares in the company, valued at approximately $1,486,989.24. The trade was a 6.57% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director William J. Chase acquired 100,000 shares of the firm's stock in a transaction that occurred on Wednesday, August 20th. The shares were bought at an average price of $10.03 per share, for a total transaction of $1,003,000.00. Following the completion of the purchase, the director owned 134,693 shares in the company, valued at $1,350,970.79. This trade represents a 288.24% increase in their position. The disclosure for this purchase can be found here. Insiders have sold a total of 12,534 shares of company stock worth $153,837 in the last ninety days. Insiders own 3.10% of the company's stock.

Institutional Trading of Intellia Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in NTLA. Northern Trust Corp raised its stake in shares of Intellia Therapeutics by 13.0% during the 4th quarter. Northern Trust Corp now owns 979,137 shares of the company's stock valued at $11,417,000 after purchasing an additional 112,847 shares during the period. Deutsche Bank AG raised its stake in shares of Intellia Therapeutics by 12.1% during the 4th quarter. Deutsche Bank AG now owns 252,501 shares of the company's stock valued at $2,944,000 after purchasing an additional 27,282 shares during the period. Ensign Peak Advisors Inc raised its stake in shares of Intellia Therapeutics by 2.9% during the 4th quarter. Ensign Peak Advisors Inc now owns 39,169 shares of the company's stock valued at $457,000 after purchasing an additional 1,100 shares during the period. Lazard Asset Management LLC raised its stake in shares of Intellia Therapeutics by 7.3% during the 4th quarter. Lazard Asset Management LLC now owns 109,500 shares of the company's stock valued at $1,276,000 after purchasing an additional 7,488 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Intellia Therapeutics by 7.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 227,255 shares of the company's stock worth $2,647,000 after acquiring an additional 15,888 shares during the last quarter. 88.77% of the stock is currently owned by institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.